Cargando…
Efficacy and safety of zuranolone in major depressive disorder: a meta-analysis of factor effect and dose-response analyses
BACKGROUND: Zuranolone is recognised as a promising antidepressant agent. Our study aimed to investigate the efficacy and safety of zuranolone in treating major depressive disorder (MDD). METHODS: A systematic review was conducted by searching major databases from inception to August 20, 2023 (INPLA...
Autores principales: | Lin, Yu-Wei, Tu, Yu-Kang, Hung, Kuo-Chuan, Liang, Chih-Sung, Tseng, Ping-Tao, Lin, Pao-Yen, Chia-Cheng Lai, Edward, Hsu, Chih-Wei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690540/ https://www.ncbi.nlm.nih.gov/pubmed/38045802 http://dx.doi.org/10.1016/j.eclinm.2023.102308 |
Ejemplares similares
-
Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial
por: Deligiannidis, Kristina M., et al.
Publicado: (2021) -
Rapid improvements in MADRS with zuranolone in major depressive disorder and postpartum depression: results from the LANDSCAPE/NEST clinical development programmes
por: Clayton, A. H., et al.
Publicado: (2023) -
Clinical Efficacy of a 2-Week Treatment Course of Zuranolone for the Treatment of Major Depressive Disorder and Postpartum Depression: Outcomes From the Clinical Development Program
por: Clayton, A., et al.
Publicado: (2022) -
Comparative effectiveness of valproic acid in different serum concentrations for maintenance treatment of bipolar disorder: A retrospective cohort study using target trial emulation framework
por: Chen, Yang-Chieh Brian, et al.
Publicado: (2022) -
Increased Risk of Asthma and Allergic Rhinitis in Patients With a Past History of Kawasaki Disease: A Systematic Review and Meta-Analyses
por: Lei, Wei-Te, et al.
Publicado: (2021)